Ostarine MK-2866
Ostarine MK-2886 is a nonsteroidal selective androgen receptor modulator (SARM) with tissue selective anabolic and androgenic pharmacological activity. It is also known in the literature as enbosarm, GTx-024 or S-22.
Originally discovered in 1998 by James T. Dalton , Duane D. Miller, Karen A. Veverka and their research teams on respectively de Ohio State University , from University of Tennessee and GTx. GTx has licensed the use of enbosarm from those research teams and has further licensed the development of MK2886 with Merck and Co.
MK-2886 is one of the first SARMS synthesized and studied in rats and primates. As a result, it is one of the most extensively researched SARMS.
One study was conducted at the cellular level of adult rats, specifically the adipocytes or fat cells. With the administration of MK-2886 Ostarine, the expression of fat-mediating hormones such as leptin and adiponectin mRNAs was reduced. Because of these effects, researchers concluded that MK-2886 Ostarine would likely behave similarly to testosterone at the AR receptors and reduce rat body fat. https://pubmed.ncbi.nlm.nih.gov/31642815/
In addition to the potential for fat loss, MK-2886 Ostarine has also been shown to stimulate bone growth in rats. One study removed part of the tibia from 4 groups of rats and then administered increasing SARM values (0.04, 0.4 and 4 mg/kg) for 5 weeks. At the highest dose, 4 mg/kg, subjects showed denser bone growth, longer bone healing time and higher markers of bone growth hormones such as phosphorus and alkaline phosphatase.
Interestingly, all rats in the study group showed increased weight of gastrocnemius muscle relative to rats not treated with MK-2886, even at the lowest dose levels (0.04 mg/kg, a 100-fold decrease over of the highest dose group).
Serum cholesterol levels were also reduced in this treatment group and the median dose group (0.4 mg/kg). The improved lipid profile of the mice was also noted in the earliest studies of MK-2886. https://pubmed.ncbi.nlm.nih.gov/31531719/
Another study produced similar results, in which rats with clinically induced osteoporosis showed increased bone density in the long bones (such as the femurs, bone growth was not noted in the vertebrae) in rats treated with moderate to high levels of MK 2866. https:/ /pubmed.ncbi.nlm.nih.gov/29785666/
A third study specifically evaluated muscle growth in mice to evaluate the function of MK-2866 in mice that were genetically engineered to lack traditional androgen receptors. Then, by removing the endogenous testosterone-producing cells from the mice, they noticed further muscle breakdown and started treatment with MK-2886. These mice experienced muscle growth in androgen-sensitive muscles, indicating a distinct pathway, distinct from sat ARKO, which encouraged muscle growth at the same level as DHT. – https://pubmed.ncbi.nlm.nih.gov/26393303/
DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or domestic use. Familiarize yourself with our DISCLAIMER before you order.
Data Sheet
Ostarine (MK-2866)
|
Application |
Selective Androgen Receptor Modulator |
|
CASE |
841205-47-8 |
|
molar massa |
389.33 g / mol |
|
Chemical Formula |
C19H14F3N3THE3 |
|
IUPAC name |
((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) |
|
Synonyms |
Ostarine, Enobosarm, GTx-024, MK-2866 |
|
Bulletin |
room temperature |
|
Solubility |
Soluble in ethanol, PEG400 |
|
Organoleptic profile |
Clear liquid |
|
Physical form |
Powder |
|
Specification |
≥98% |
|
Requirements |
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or domestic use. Please familiarize yourself with our terms and conditions & disclaimer before ordering. |
